Pfizer inks peptide deal with Sutro

Sutro Biopharma has landed a multi-year collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics. Financial details of the deal were not disclosed. The company says it's developing new and biosuperior protein therapeutics with better pharmaceutical properties. Sutro recently raised. $36.5 million in a Series C financing. Sutro release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.